Anti physcotics detailled pharmacology

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

antipsychotic pharmacology mechanisms dopamine serotonin

Reading File

I now have comprehensive content to write a detailed pharmacology response. Let me compose the full answer:

Antipsychotics: Detailed Pharmacology

1. Overview and Classification

Antipsychotic drugs reduce psychotic symptoms across a wide range of conditions - schizophrenia, bipolar disorder, psychotic depression, dementia-related psychosis, and drug-induced psychoses. They fall into two major generations:

Generation	Also Called	Prototype	Key Feature
First (FGA)	"Typical" / Neuroleptics	Chlorpromazine, Haloperidol	High D2 blockade; high EPS risk
Second (SGA)	"Atypical"	Clozapine, Olanzapine, Risperidone	Combined D2 + 5-HT2A blockade; less EPS
Third	Partial agonists	Aripiprazole, Cariprazine	D2/D3 partial agonism + 5-HT1A partial agonism

A neuroleptic specifically refers to a drug that produces catalepsy in animals and extrapyramidal effects (EPS) in humans at clinically effective doses - i.e., all FGAs.

2. The Dopamine Hypothesis and Pathways

Five dopaminergic pathways

Pathway	Origin → Projection	Clinical Relevance
Mesolimbic	Ventral tegmentum → limbic system	Mediates positive symptoms; D2 blockade here = antipsychotic effect
Mesocortical	Ventral tegmentum → neocortex/prefrontal cortex	Negative/cognitive symptoms; blockade worsens them
Nigrostriatal	Substantia nigra → caudate/putamen	Voluntary movement; D2 blockade here = EPS
Tuberoinfundibular	Arcuate nucleus → anterior pituitary portal	D2 blockade here → hyperprolactinemia
Medullary-periventricular	Motor nucleus of vagus	Involved in eating behavior

The dopamine hypothesis states that excess dopaminergic activity in the mesolimbic system underlies positive psychotic symptoms. Antipsychotics work by blocking D2 receptors, reducing this excess activity.

3. Dopamine Receptor Subtypes

Receptor	Chromosome	Second Messenger	Location	Relevance
D1	Chr 5	↑ cAMP (Gs)	Putamen, NAc, olfactory cortex	Antipsychotic potency does NOT correlate with D1 affinity
D2	Chr 11	↓ cAMP (Gi), inhibits Ca²⁺ channels, opens K⁺ channels	Caudate-putamen, NAc; pre & post-synaptic	PRIMARY target for antipsychotic action
D3	Chr 3	↓ cAMP	Limbic areas	Role in mood/cognition
D4	Chr 11	↓ cAMP	Frontal cortex, limbic	High affinity for clozapine
D5	Chr 4	↑ cAMP	Hippocampus, hypothalamus	Less well-defined role

The therapeutic potency of antipsychotic drugs correlates best with D2 receptor affinity, not D1. Antipsychotic effect requires ~60-80% D2 occupancy (by PET imaging). EPS appears when occupancy exceeds ~80%.

4. Mechanism of Action by Drug Class

4.1 First-Generation (Typical) Antipsychotics

Mechanism: Pure D2 antagonism (+ some D1, α1, H1, muscarinic)
Effect: Reduce positive symptoms (hallucinations, delusions, disorganization)
Limitation: Do NOT improve negative symptoms (flat affect, alogia, avolition); worsen them via mesocortical blockade

Receptor binding profiles (highest to lowest affinity):

Chlorpromazine (aliphatic phenothiazine): α1 = 5-HT2A > D2 > D1
Haloperidol (butyrophenone): D2 > α1 > D4 > 5-HT2A > D1 > H1
Thioridazine (piperidine phenothiazine): strong muscarinic + D2

4.2 Second-Generation (Atypical) Antipsychotics

The key pharmacological distinction is serotonin-dopamine antagonism (SDA):

Strong 5-HT2A blockade in the nigrostriatal pathway disinhibits dopamine release there, reducing EPS
D2 blockade in mesolimbic system reduces positive symptoms
The ratio of 5-HT2A:D2 blockade determines "atypicality"

Receptor binding profiles:

Clozapine: D4 = α1 > 5-HT2A > D2 = D1 (notably LOW D2 affinity; unique)
Olanzapine: 5-HT2A > H1 > D4 > D2 > α1 > D1
Quetiapine: H1 > α1 > M1,2 > D2 > 5-HT2A
Risperidone: Strong D2 + 5-HT2A antagonism + α2 blockade
Ziprasidone: D2 + 5-HT2A antagonist, also 5-HT1A partial agonist + 5-HT/NE reuptake inhibition
Aripiprazole: D2 = 5-HT2A > D4 > α1 = H1 (D2 partial agonist)

4.3 Third-Generation: Partial Agonists

Aripiprazole and brexpiprazole: D2/D3 partial agonists + 5-HT1A partial agonists + 5-HT2A antagonists
Cariprazine: D3 > D2 partial agonist (highest D3 affinity of any approved antipsychotic)
Partial agonism at D2: acts as functional antagonist when dopamine is high (limbic - reduces positive symptoms) and as agonist when dopamine is low (cortical - may improve negative/cognitive symptoms)
This dual action is the theoretical basis for superiority in negative and cognitive symptoms

5. Pharmacokinetics

Parameter	Details
Absorption	Most well-absorbed orally; significant first-pass metabolism
Distribution	High Vd (highly lipophilic); extensive tissue binding
Protein binding	90-99% bound to plasma proteins
Metabolism	Primarily hepatic via CYP enzymes (CYP1A2, CYP2D6, CYP3A4)
Half-lives	Variable: haloperidol ~24h; chlorpromazine ~30h; aripiprazole ~75h; clozapine ~12h; quetiapine ~6-7h
Excretion	Mainly renal (metabolites); some biliary
Depot forms	Fluphenazine decanoate, haloperidol decanoate, risperidone microspheres, paliperidone palmitate, aripiprazole lauroxil - half-lives of weeks

Plasma levels: For most antipsychotics, plasma levels correlate better with response than prescribed dose. A 12-hour trough level is standard for oral agents. Point of futility = level beyond which response rates fall below 5%.

6. Indications

Indication	Notes
Schizophrenia	Primary indication; positive symptoms best treated
Bipolar mania	SGAs effective as monotherapy in acute phase; some approved for maintenance
Bipolar depression	Quetiapine, lurasidone, cariprazine, lumateperone FDA-approved
Unipolar depression (adjunct)	Aripiprazole, quetiapine, brexpiprazole, olanzapine+fluoxetine
Schizoaffective disorder	Often combined with mood stabilizers
Acute agitation	IM haloperidol, IM olanzapine, IM ziprasidone, IM aripiprazole
Tourette's disorder	Haloperidol, pimozide, aripiprazole
Antiemetic	Prochlorperazine, metoclopramide (phenothiazine class)
Treatment-resistant schizophrenia	Clozapine (40-60% response vs. <5% for most others)

7. Adverse Effects

7.1 Extrapyramidal Symptoms (EPS) - Neurological

Reaction	Time of Onset	Features	Management
Acute dystonia	Hours to days	Involuntary muscle spasm (torticollis, oculogyric crisis, opisthotonus)	Anticholinergic (benztropine IM/IV, diphenhydramine)
Parkinsonism	Days to weeks	Bradykinesia, rigidity, tremor, shuffling gait	Reduce dose; add anticholinergic or amantadine (NOT levodopa)
Akathisia	Days to weeks	Subjective restlessness, inability to sit still; most distressing	Reduce dose; propranolol; benzodiazepine; switch to SGA
Tardive dyskinesia (TD)	Months to years	Repetitive involuntary movements (lip smacking, tongue protrusion, chorea); due to dopamine receptor supersensitivity	Reduce/stop offending drug; switch to clozapine; valbenazine or deutetrabenazine

Risk of TD: ~7.2% with SGAs (no prior FGA exposure); higher with FGAs.

7.2 Neuroleptic Malignant Syndrome (NMS)

Rare but life-threatening idiosyncratic reaction
Features: Hyperthermia, muscle rigidity, altered consciousness, autonomic instability (tachycardia, labile BP, diaphoresis)
Lab: Elevated CK, leukocytosis, myoglobinuria
Management: Stop drug immediately; supportive care; dantrolene (muscle relaxant), bromocriptine (dopamine agonist); ICU admission

7.3 Metabolic Effects

Effect	Risk Ranking (Worst to Best)
Weight gain	Clozapine > Olanzapine > Quetiapine/Asenapine > Risperidone/Lurasidone > Ziprasidone/Aripiprazole
Dyslipidemia (hypertriglyceridemia)	Clozapine, Olanzapine highest risk
New-onset diabetes	Clozapine, Olanzapine most associated

7.4 Hyperprolactinemia

Due to tuberoinfundibular D2 blockade
Effects: Galactorrhea, amenorrhea, gynecomastia, sexual dysfunction, decreased bone density
Worst with: Risperidone, haloperidol, FGAs
Best: Aripiprazole (D2 partial agonist - may actually lower prolactin), quetiapine, clozapine

7.5 Antimuscarinic Effects (especially FGAs)

Dry mouth, blurred vision, urinary retention, constipation, tachycardia, toxic confusional state
Most prominent with: Chlorpromazine, thioridazine, clozapine

7.6 Cardiovascular Effects

QTc prolongation: Thioridazine (most - removed from most markets), ziprasidone, haloperidol IV - risk of Torsades de Pointes
Orthostatic hypotension: α1 blockade - chlorpromazine, clozapine, quetiapine
Clozapine-specific: Myocarditis (1-2% risk, most in first 6-8 weeks), cardiomyopathy

7.7 Hematologic Effects (Clozapine-Specific)

Agranulocytosis in up to 1-2% of patients
Requires mandatory REMS (Risk Evaluation and Mitigation Strategy) monitoring:
- WBC weekly for 6 months, then every 2 weeks for 6 months, then monthly
Leukopenia: Interrupt treatment; patients may be retreated if WBC normalizes
Seizure threshold lowered (dose-dependent); seizures in ~3-5% at high doses

7.8 Endocrine & Other Effects

Weight gain and insulin resistance (especially clozapine, olanzapine)
Neuroendocrine: ↓ GnRH pulsatility → hypogonadism with chronic hyperprolactinemia
Skin: Photosensitivity (chlorpromazine - grey-blue discoloration with prolonged use)
Ocular: Lens and corneal opacities (chlorpromazine); retinal pigmentation (thioridazine)
Hypothermia or fever (poikilothermia - impaired thermoregulation)

8. Drug-Specific Profiles

Clozapine

Most effective antipsychotic (40-60% response in treatment-resistant schizophrenia vs. <5% for others)
Why unique: Very low D2 affinity; highest D4, 5-HT2A, muscarinic, α1, H1 binding
Mechanism not fully understood - not primarily via D2 blockade
Therapeutic plasma level: minimum ~350 ng/mL for treatment-resistant cases; seizure risk >1200 ng/mL
Monitoring: ANC/WBC (agranulocytosis), metabolic panel, ECG, cardiac enzymes (myocarditis)

Haloperidol

Prototype FGA butyrophenone
Very high D2 affinity → most EPS of all antipsychotics
Available IM (acute) and decanoate depot (monthly)
Useful in ICU delirium management

Risperidone/Paliperidone

Strong D2 + 5-HT2A blockade
Highest prolactin elevation among SGAs
Low-dose: minimal EPS; higher dose: EPS emerges
Paliperidone = active metabolite (9-OH-risperidone), renally cleared
Available as 1-month (Risperdal Consta) and 3-month (Perseris) depot

Olanzapine

Broad receptor blockade (5-HT2A, H1, D2, muscarinic, α1)
Very effective but worst metabolic profile after clozapine
7-9% response in treatment-resistant schizophrenia (best non-clozapine option)
IM form for acute agitation

Quetiapine

Weakest D2 affinity of all SGAs; short half-life (twice-daily dosing for antipsychotic effect)
High H1 and α1 blockade → sedation, orthostasis
Active metabolite norquetiapine: NE reuptake inhibitor → antidepressant properties
Widely used (off-label) for insomnia and anxiety (sedation at low doses)

Aripiprazole

D2/D3 partial agonist + 5-HT1A partial agonist + 5-HT2A antagonist
Lowest prolactin elevation (may lower prolactin)
Longest half-life (~75 hours); active metabolite dehydro-aripiprazole also long-acting
Least metabolic burden among SGAs

Ziprasidone

Least weight gain among SGAs
Significant QTc prolongation (caution with other QT-prolonging drugs)
Must be taken with food (doubles bioavailability)

Cariprazine

D3 > D2 partial agonist (unique D3 selectivity among all approved agents)
Approved for schizophrenia AND bipolar depression
D3 receptor modulation hypothetically improves cognitive and negative symptoms

Lumateperone

5-HT2A antagonist + D2 partial agonist + glutamate AMPA modulation + SERT inhibition
Once-daily dosing
Approved for schizophrenia, bipolar depression (MDD adjunct)
Favorable metabolic and EPS profile

9. Comparison Summary Table

Drug	D2	5-HT2A	H1	M1	α1	EPS Risk	Weight Gain	Prolactin	Special Feature
Haloperidol	+++++	+	+	+	++	+++++	+	++++	High EPS; depot available
Chlorpromazine	+++	+++	++++	++++	++++	+++	+++	+++	Many autonomic effects
Clozapine	+	+++	++++	+++++	++++	0	+++++	0	Agranulocytosis; best for TRS
Olanzapine	+++	++++	++++	+++	++	+	+++++	+	Broadest efficacy; metabolic risk
Risperidone	++++	++++	++	0	++	++	++	+++++	Highest prolactin elevation
Quetiapine	++	++	+++++	++	++++	0	+++	0	Most sedating; depression use
Ziprasidone	+++	++++	++	+	++	+	0	+	QTc prolongation; least weight gain
Aripiprazole	PA	+++	+	+	++	+	+	0↓	D2 partial agonist; lowest prolactin
Cariprazine	PA(D3>>D2)	++	+	+	+	+	+	+	D3-selective partial agonist

PA = Partial agonist; TRS = Treatment-resistant schizophrenia

10. Pharmacology of EPS Prevention/Treatment

Anticholinergics (benztropine, trihexyphenidyl): Block muscarinic receptors in striatum; restore the ACh/DA balance disrupted by D2 blockade
Amantadine: Dopamine-releasing + weak NMDA antagonist; used for Parkinsonism (avoid levodopa)
Beta-blockers (propranolol): First choice for akathisia
Benzodiazepines: Second choice for akathisia

11. Special Considerations

Pregnancy

Antipsychotics cross the placenta; neonates exposed in 3rd trimester may show EPS and withdrawal symptoms
Risk of gestational diabetes (especially clozapine/olanzapine)
Generally, the risk of untreated psychosis outweighs drug risks

Elderly

Increased sensitivity to EPS, orthostasis, anticholinergic effects, and sedation
Black box warning: Increased mortality in elderly with dementia-related psychosis

Drug Interactions

CYP1A2 inducers (smoking, carbamazepine): ↓ clozapine, olanzapine levels
CYP2D6 inhibitors (fluoxetine, paroxetine): ↑ haloperidol, risperidone levels
QTc-prolonging drugs: Additive risk with ziprasidone, thioridazine

Key Sources:

Katzung's Basic and Clinical Pharmacology, 16th Ed., Ch. 29 (Antipsychotic Agents & Lithium)
Goodman & Gilman's Pharmacological Basis of Therapeutics, Antipsychotic Agents section
Kaplan & Sadock's Synopsis of Psychiatry

Recent evidence note: A 2026 review on clozapine's unique efficacy in treatment-resistant schizophrenia (Murray et al., Biol Psychiatry 2026; PMID 40562225) proposes glutamatergic and serotonergic mechanisms - beyond D2 - as central to clozapine's superiority, which may refine understanding of its mechanism.

Sedatives detailed pharaoh

Finding Sources

Reading File

Finding Sources

Searching PubMed

sedative hypnotic pharmacology GABA benzodiazepine

Reading File

I now have comprehensive content to deliver a detailed, well-organized answer. Here it is:

Sedatives: Detailed Pharmacology

1. Definition and Classification

A sedative (anxiolytic) reduces anxiety and exerts a calming effect. A hypnotic produces drowsiness and encourages sleep onset and maintenance. These are dose-dependent effects of the same drug class - hypnosis is simply more pronounced CNS depression than sedation, achieved by increasing the dose.

Classification by mechanism:

Class	Prototype Drugs
Benzodiazepines (BZDs)	Diazepam, lorazepam, alprazolam, triazolam
Barbiturates	Phenobarbital, thiopental, secobarbital
Z-drugs (non-BZD hypnotics)	Zolpidem, zaleplon, eszopiclone
Melatonin receptor agonists	Ramelteon, tasimelteon
Orexin receptor antagonists	Suvorexant, lemborexant
Azapirones (atypical anxiolytics)	Buspirone
Older miscellaneous	Chloral hydrate, meprobamate

2. The GABA-A Receptor: Master Target

All major sedative-hypnotics (BZDs, barbiturates, Z-drugs, alcohol, propofol, etomidate) act on the GABA-A receptor-chloride channel complex - the most pharmacologically versatile receptor in the CNS.

Structure

The GABA-A receptor is a pentameric ligand-gated Cl⁻ ion channel assembled from five subunits selected from multiple classes:

α (6 subtypes), β (4 subtypes), γ (3 subtypes), δ, ε, π, ρ
A major brain isoform: 2α1 + 2β2 + 1γ2

Binding Sites

Drug	Binding Site	Mechanism
GABA	Between α and β subunits (2 sites)	Opens Cl⁻ channel
Benzodiazepines	Between α and γ subunits (BZ site)	Increases frequency of Cl⁻ channel opening (allosteric potentiation of GABA)
Barbiturates	Separate site on β subunit	Increases duration of Cl⁻ channel opening; at high doses, directly opens channel (GABA-independent)
Z-drugs (zolpidem, zaleplon, eszopiclone)	Same BZ site as benzodiazepines	Same as BZDs but subunit-selective (α1 >> α2, α3)
Neurosteroids (alphaxalone)	Distinct transmembrane site	Allosteric potentiation
Propofol, etomidate	Transmembrane domain (α2/α3 preferred)	Allosteric potentiation
Picrotoxin	Inside channel pore	Blocks Cl⁻ channel (convulsant)
Bicuculline	GABA binding site	Blocks GABA binding (convulsant)

Net effect of GABA-A activation: Cl⁻ influx → membrane hyperpolarization → reduced neuronal excitability.

Key distinction:

BZDs: increase frequency of channel opening (GABA must be present)
Barbiturates: increase duration of channel opening; can open channel WITHOUT GABA at high doses
This explains why barbiturate overdose has a much narrower safety margin

3. Benzodiazepines

3.1 Chemistry

All are 1,4-benzodiazepine ring structures with a carboxamide group. A halogen or nitro group at the 7-position is required for sedative-hypnotic activity. Triazolam and alprazolam have an additional triazole ring at the 1,2-position (triazolobenzodiazepines).

3.2 Mechanism of Action

BZDs are positive allosteric modulators of GABA-A receptors. They bind to the BZ site (between α and γ2 subunits) and increase the frequency of Cl⁻ channel opening in the presence of GABA. They have no intrinsic activity without GABA - hence their safety ceiling. They bind to receptor isoforms containing α1, α2, α3, and α5 subunits:

α1 subunits: sedation, amnesia, anticonvulsant effects
α2/α3 subunits: anxiolytic and muscle relaxant effects

3.3 Pharmacokinetics

Absorption: Well absorbed orally; onset varies with lipid solubility.

Distribution: High lipid solubility → rapid CNS entry. All cross the placenta and appear in breast milk.

Metabolism: All metabolized hepatically.

Phase I: CYP3A4-mediated N-dealkylation and hydroxylation
Phase II: Glucuronide conjugation → urinary excretion
Many produce active metabolites with long half-lives

Drug	Active Metabolite	t½ of Metabolite
Diazepam	Desmethyldiazepam	>40 hours
Chlordiazepoxide	Desmethyldiazepam	>40 hours
Clorazepate	Desmethyldiazepam	>40 hours
Alprazolam	α-OH-alprazolam (short-lived)	Rapidly conjugated
Triazolam	α-OH-triazolam (short-lived)	Rapidly conjugated
Lorazepam, oxazepam, temazepam	None (LOT drugs)	Only parent drug

"LOT" drugs (Lorazepam, Oxazepam, Temazepam): directly conjugated to inactive glucuronides - safest in liver disease and elderly; no active metabolites, no accumulation.

3.4 Duration Classification

Category	Drugs	t½	Clinical Use
Ultra-short	Triazolam	2-3 h	Sleep onset
Short	Alprazolam, lorazepam, oxazepam, temazepam	6-24 h	Anxiety, procedural sedation
Intermediate	Clonazepam, estazolam	20-40 h	Anxiety, seizures
Long	Diazepam, chlordiazepoxide, clorazepate	20-100 h (with active metabolites >200 h)	Alcohol withdrawal, muscle spasm

3.5 Effects on Sleep Architecture

↓ Sleep onset latency (time to fall asleep)
↑ Stage 2 NREM duration
↓ REM sleep duration
↓ Stage 3 NREM (slow-wave/deep sleep)

Reduced slow-wave sleep and REM suppression can impair sleep quality with chronic use.

3.6 Organ System Effects

System	Effect
CNS	Anxiolysis, sedation, amnesia (anterograde), anticonvulsant, muscle relaxation
Respiratory	Dose-dependent depression; dangerous with opioids or alcohol
Cardiovascular	Minimal at therapeutic doses; IV may cause transient hypotension
Skeletal muscle	Relaxation via spinal interneuron inhibition

Anterograde amnesia: Inability to form new memories during the drug's duration of action - used intentionally for procedural sedation (e.g., endoscopy, cardioversion).

3.7 Clinical Indications

Anxiety disorders (GAD, panic disorder, social phobia)
Insomnia (short-term use only)
Alcohol and sedative-hypnotic withdrawal (diazepam, chlordiazepoxide)
Seizure disorders (clonazepam, diazepam IV for status epilepticus)
Procedural sedation and premedication (midazolam, lorazepam)
Muscle relaxation (diazepam)
Catatonia (IV lorazepam - first-line)
Acute agitation in bipolar/schizophrenia (lorazepam adjunct)

4. Barbiturates

4.1 Mechanism

Barbiturates bind to a site distinct from BZDs on the GABA-A receptor (on β subunits). They:

Increase the duration of Cl⁻ channel opening
At high doses: directly open the Cl⁻ channel independent of GABA - this is why they have a narrow therapeutic index and cause respiratory depression and death in overdose

No ceiling effect - unlike BZDs, respiratory centers are directly suppressed as dose increases (linear dose-response curve).

4.2 Subclassification

Type	Drug	t½	Use
Ultra-short	Thiopental, methohexital	5-15 min (redistribution)	IV induction of anesthesia
Short-intermediate	Secobarbital, pentobarbital	20-30 h	Sedation, insomnia (rare now)
Long-acting	Phenobarbital	80-120 h	Epilepsy, neonatal seizures

4.3 Pharmacokinetics

Lipid solubility determines onset: thiopental = ultra-high → immediate CNS effect, then rapid redistribution to muscle and fat
Metabolized by hepatic microsomal enzymes
Phenobarbital induces CYP enzymes (CYP2C9, CYP3A4) - important drug interaction source

4.4 CNS Effects

Progressive CNS depression: sedation → hypnosis → anesthesia → coma → death
EEG: burst suppression at anesthetic doses
No anxiolytic specificity - equal sedation/anxiolysis
Disinhibition and euphoria possible at low doses (abuse potential)

4.5 Why Largely Replaced

Narrow therapeutic index
Lethal in overdose (direct GABA-independent channel opening)
High abuse potential
Enzyme induction causing many drug interactions
Physical dependence and severe withdrawal (life-threatening)

Phenobarbital remains used for epilepsy (especially developing world) and neonatal seizures. Thiopental/methohexital remain in anesthesia.

5. Z-Drugs (Non-Benzodiazepine Hypnotics)

5.1 Drugs and Structure

Drug	Chemical Class	t½
Zolpidem	Imidazopyridine	2-3 h
Zaleplon	Pyrazolopyrimidine	1 h
Eszopiclone	Cyclopyrrolone (S-enantiomer of zopiclone)	6 h

Structurally unrelated to BZDs but act at the same BZ binding site on GABA-A receptors.

5.2 Key Difference from BZDs

Z-drugs show subunit selectivity:

Bind preferentially to α1-containing GABA-A receptors
α1 receptors mediate: sedation, amnesia, anticonvulsant effects
α2/α3 (anxiolytic, muscle relaxant effects) are less activated
Result: Better hypnotic profile with less anxiolysis and muscle relaxation
Flumazenil (BZD antagonist) reverses their effects

5.3 Effects on Sleep

Zolpidem: ↓ sleep latency; ↓ REM sleep; minimal effect on slow-wave sleep; approved for sleep onset AND maintenance (extended-release)
Zaleplon: Very short t½ - best for sleep onset only; can be redosed in middle of night
Eszopiclone: ↓ sleep latency; improves sleep maintenance; longest t½ of Z-drugs; approved for long-term use (only FDA-approved hypnotic without duration limit)

5.4 Adverse Effects

Next-day sedation and psychomotor impairment (especially zolpidem in women - lower doses recommended)
Paradoxical behaviors: Sleep-walking, sleep-eating, sleep-driving (sleep-related complex behaviors) - FDA black box warning for zolpidem; most common with higher doses or combined with CNS depressants
Amnesia, dizziness, headache
Dependence and withdrawal (like BZDs, but generally milder)
Elderly: Falls, cognitive impairment (avoid if possible)
No antiseizure activity (unlike BZDs)
Metabolized by CYP3A4

6. Melatonin Receptor Agonists

Ramelteon (MT1 + MT2 agonist)

Acts at MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) - the biological clock
MT1: Suppresses the alerting signal of SCN neurons (promotes sleep onset)
MT2: Shifts circadian phase
No GABA involvement - no dependence, no abuse potential, not a controlled substance
No significant respiratory depression
Metabolized by CYP1A2 to active metabolite (M-II); fluvoxamine (CYP1A2 inhibitor) dramatically increases levels - avoid combination
Used for sleep-onset insomnia; minimal effect on sleep maintenance
Adverse effects: Dizziness, fatigue, endocrine effects (↓ testosterone, ↑ prolactin with chronic use)

Tasimelteon

MT1 + MT2 agonist
FDA-approved for non-24-hour sleep-wake disorder (common in totally blind individuals with disrupted circadian entrainment)

7. Orexin (Hypocretin) Receptor Antagonists (DORAs)

Mechanism

Orexins (hypocretins 1 and 2) are neuropeptides from lateral hypothalamus that promote and maintain wakefulness. They act on OX1 and OX2 receptors widely distributed in arousal centers (locus coeruleus, dorsal raphe, histaminergic tuberomammillary nucleus)
DORAs block OX1 and OX2 receptors → remove the wakefulness drive → passive sleep induction (vs. active CNS depression by BZDs)

Drugs

Drug	t½	Dose	Note
Suvorexant	12 h	10 mg at bedtime	Promotes both sleep onset and maintenance
Lemborexant	17-19 h	5 mg at bedtime	Approved sleep onset and maintenance

Advantages over GABA-ergic agents

No respiratory depression
No cognitive impairment at therapeutic doses
No dependence or abuse potential (not scheduled)
No rebound insomnia

Adverse Effects

Next-day somnolence (most common)
Sleep paralysis, hypnagogic/hypnopompic hallucinations (narcolepsy-like symptoms)
Metabolized by CYP3A4 - inhibitors (fluconazole, verapamil, grapefruit juice) increase levels

8. Buspirone (Azapirone)

Mechanism

5-HT1A partial agonist (presynaptic > postsynaptic)
Also has D2 receptor affinity (weak antagonist) - but does NOT act on GABA-A receptors
Slow onset of anxiolytic action: 1-2 weeks (compared to immediate effect of BZDs)

Key Features

Feature	Detail
Indication	Generalized anxiety disorder (GAD) only
Onset	1-2 weeks (not useful for acute anxiety)
No cross-tolerance	Does NOT work in BZD-tolerant/dependent patients; cannot prevent BZD withdrawal
No sedation	Minimal psychomotor impairment
No abuse potential	Not a controlled substance
Short t½	Twice to thrice daily dosing; forms active metabolite (1-PP, D2 antagonist)
Adverse effects	Tachycardia, paresthesias, GI distress, dizziness

9. Tolerance, Dependence, and Withdrawal

Tolerance

Pharmacodynamic tolerance: Down-regulation of GABA-A receptor subunits and uncoupling of receptor from Cl⁻ channel with chronic use
Develops faster to sedative/hypnotic effects than to anxiolytic or anticonvulsant effects
Cross-tolerance exists within the class (BZDs, barbiturates, alcohol, Z-drugs)

Physical Dependence and Withdrawal

BZD/Barbiturate Withdrawal Syndrome - potentially life-threatening:

Timeline: Onset 1-3 days after stopping short-acting agents; up to 1 week for long-acting
Features: Anxiety, insomnia, tremor, diaphoresis, tachycardia, hypertension, seizures
Severity: Can progress to delirium and death (similar to alcohol withdrawal)
Management: Long-acting BZD taper (diazepam or chlordiazepoxide); phenobarbital taper

Contrast with opioid withdrawal: Opioid withdrawal is extremely uncomfortable but rarely fatal. BZD/barbiturate withdrawal CAN be fatal due to seizures.

10. Adverse Effects Summary

Effect	BZDs	Barbiturates	Z-drugs	Notes
Respiratory depression	++	++++	+	Barbiturates most dangerous; additive with opioids
Anterograde amnesia	+++	++	++	Exploited for procedural sedation
Cognitive impairment	++	+++	+	Significant in elderly
Tolerance	++	++++	++	Faster with barbiturates
Dependence	++	++++	++	Severe with barbiturates
Withdrawal seizures	++	+++++	+	Life-threatening for barbiturates
Overdose lethality	Low	HIGH	Low	BZD alone rarely fatal; barbiturate OD = high mortality
Paradoxical behaviors	+	+	+++	Sleep-driving, sleep-eating (Z-drugs)
Drug interactions	++	+++++	+	Barbiturate enzyme induction is major

Flumazenil (BZD Antagonist)

Competitive antagonist at the BZ site on GABA-A receptor
Reverses sedation from BZDs and Z-drugs (NOT barbiturates, alcohol, or opioids)
IV; very short t½ (0.7-1.3 h) → sedation recurs; repeated doses needed
Danger: Can precipitate acute withdrawal/seizures in BZD-dependent patients
Caution with concurrent TCA ingestion: may unmask seizures/arrhythmias

11. Drug Interactions

Interaction	Mechanism	Result
BZDs + opioids	Additive GABA-ergic + opioid-mediated respiratory depression	Severe respiratory depression, death (FDA black box warning)
BZDs + alcohol	Additive CNS depression	Respiratory depression, coma
Barbiturates + oral contraceptives	CYP induction ↑ OCP metabolism	OCP failure
Barbiturates + warfarin	CYP induction ↑ warfarin metabolism	↓ anticoagulation
Valproate + phenobarbital	Valproate inhibits phenobarbital metabolism	↑ phenobarbital toxicity
Diazepam + CYP3A4 inhibitors	↑ BZD levels	Over-sedation
Fluvoxamine + ramelteon	CYP1A2 inhibition	Massive ↑ ramelteon levels
Suvorexant + azole antifungals	CYP3A4 inhibition	↑ suvorexant levels, next-day impairment

12. Special Populations

Pregnancy

All sedative-hypnotics cross the placenta
BZDs: Risk of neonatal withdrawal and respiratory depression if given near delivery; cleft palate association (BZDs) - data debated
"Floppy infant syndrome" with late-pregnancy BZD use

Elderly

LOT drugs (lorazepam, oxazepam, temazepam) preferred - no active metabolites
Avoid long-acting BZDs (diazepam) - prolonged sedation, fall risk
Beers Criteria: BZDs and Z-drugs listed as potentially inappropriate in elderly

Hepatic Impairment

LOT drugs safe (only phase II glucuronidation, preserved in liver disease)
Other BZDs: Accumulate (reduced phase I metabolism)

13. Comparative Summary

Drug	MOA	Onset	t½	Abuse	Overdose Risk	Key Use
Diazepam	GABA-A (BZ site)	Fast	Very long	Yes	Low (alone)	Anxiety, alcohol WD, seizures
Lorazepam	GABA-A (BZ site)	Intermediate	Short	Yes	Low	Procedural sedation, status epilepticus
Triazolam	GABA-A (BZ site)	Fast	Ultra-short	Yes	Low	Sleep onset only
Phenobarbital	GABA-A (distinct site)	Slow	Very long	Yes	HIGH	Epilepsy
Thiopental	GABA-A (distinct site)	Ultra-fast	Ultra-short (redistrib.)	Yes	HIGH	IV anesthesia induction
Zolpidem	GABA-A (BZ site, α1 selective)	Fast	Short	Yes	Low	Sleep onset/maintenance
Zaleplon	GABA-A (BZ site, α1 selective)	Very fast	Ultra-short	Yes	Low	Sleep onset (mid-night redosing)
Eszopiclone	GABA-A (BZ site)	Fast	Intermediate	Yes	Low	Sleep onset + maintenance
Ramelteon	MT1/MT2 agonist	Fast	Short	No	Very low	Sleep-onset insomnia
Suvorexant	OX1/OX2 antagonist	Intermediate	Long	No	Very low	Sleep onset + maintenance insomnia
Buspirone	5-HT1A partial agonist	Slow (1-2 wk)	Short	No	Very low	GAD only

Key Sources:

Katzung's Basic and Clinical Pharmacology, 16th Ed., Ch. 22 (Sedative-Hypnotic Drugs)
Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 17 (Hypnotics & Sedatives)

Recent evidence update: A 2024 review on orexin antagonists (suvorexant/lemborexant) confirms their efficacy for both sleep-onset and maintenance insomnia with a superior safety profile vs. BZDs, supporting their growing role as first-line agents. A 2024-2025 body of work on remimazolam (a new ultra-short-acting BZD ester metabolized by tissue esterases, t½ ~5-10 min) establishes it as a novel procedural sedation agent [PMID 39443046, PMID 40690147], now used for procedural and ICU sedation as an alternative to midazolam and propofol.

This is a shared conversation. Sign in to Orris to start your own chat.